Results, rhetoric, and randomized trials: the case of donepezil.
about
A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Drugs for Alzheimer's disease: are they effective?The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis.The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias.
P2860
Results, rhetoric, and randomized trials: the case of donepezil.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Results, rhetoric, and randomized trials: the case of donepezil.
@ast
Results, rhetoric, and randomized trials: the case of donepezil.
@en
Results, rhetoric, and randomized trials: the case of donepezil.
@nl
type
label
Results, rhetoric, and randomized trials: the case of donepezil.
@ast
Results, rhetoric, and randomized trials: the case of donepezil.
@en
Results, rhetoric, and randomized trials: the case of donepezil.
@nl
prefLabel
Results, rhetoric, and randomized trials: the case of donepezil.
@ast
Results, rhetoric, and randomized trials: the case of donepezil.
@en
Results, rhetoric, and randomized trials: the case of donepezil.
@nl
P2860
P1476
Results, rhetoric, and randomized trials: the case of donepezil.
@en
P2093
John R Gilstad
Thomas E Finucane
P2860
P304
P356
10.1111/J.1532-5415.2008.01844.X
P407
P577
2008-07-24T00:00:00Z